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Abstract
Gene targeting is progressively becoming a realistic therapeutic
alternative in clinics. It is unknown, however, whether this tech-
nology will be suitable for the treatment of DNA repair deficiency
syndromes such as Fanconi anemia (FA), with defects in homology-
directed DNA repair. In this study, we used zinc finger nucleases
and integrase-defective lentiviral vectors to demonstrate for the
first time that FANCA can be efficiently and specifically targeted
into the AAVS1 safe harbor locus in fibroblasts from FA-A patients.
Strikingly, up to 40% of FA fibroblasts showed gene targeting
42 days after gene editing. Given the low number of hematopoi-
etic precursors in the bone marrow of FA patients, gene-edited FA
fibroblasts were then reprogrammed and re-differentiated toward
the hematopoietic lineage. Analyses of gene-edited FA-iPSCs
confirmed the specific integration of FANCA in the AAVS1 locus in
all tested clones. Moreover, the hematopoietic differentiation of
these iPSCs efficiently generated disease-free hematopoietic
progenitors. Taken together, our results demonstrate for the first
time the feasibility of correcting the phenotype of a DNA repair
deficiency syndrome using gene-targeting and cell reprogramming
strategies.
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Introduction
The progressive development of engineered nucleases has markedly
improved the efficacy and specificity of targeted gene therapy, open-
ing new possibilities for the treatment of inherited and acquired
diseases in the clinics (Tebas et al, 2014). In contrast to conven-
tional gene therapy with integrative vectors, targeted gene therapy
enables the insertion of foreign sequences (i.e., therapeutic genes or
small oligonucleotides) in specific sites of the cell genome. Thus,
depending on the genetic etiology of the disease, the gene-targeting
approach may pursue the correction of a specific mutation or, alter-
natively, the insertion of the therapeutic transgene into safe loci of
the genome, often referred to as ‘safe harbors’ (Naldini, 2011).
In spite of the advances in the field, the question of whether or
not targeted gene therapy will be applicable to diseases where
homology-directed repair (HDR) is affected has never been explored.
Taking into account that Fanconi anemia (FA) proteins participate in
HDR (Taniguchi et al, 2002; Yamamoto et al, 2003; Niedzwiedz
et al, 2004; Yang et al, 2005; Nakanishi et al, 2011) and coordinate
the action of multiple DNA repair processes, including the action of
different nucleases and homologous recombination (see reviews in
Kee & D’Andrea, 2010; Kottemann & Smogorzewska, 2013; Moldo-
van & D’Andrea, 2009), we aimed to investigate for the first time the
possibility of conducting a targeted gene therapy strategy in FA cells.
Genetically, FA is a complex disease where mutations in sixteen
different genes (FANC-A, -B, -C, -D1/BRCA2, -D2, -E, -F, -G, -I, -J/
BRIP1, -L –M, –N/PALB2, -O/RAD51C; -P/SLX4; -Q/ERCC4/XPF) have
been reported (Bogliolo et al, 2013). Among all these genes, muta-
tions in FANCA account for about 60% of total FA patients (Casado
et al, 2007; Auerbach, 2009). Importantly, while few recurrent
mutations (i.e., truncation of exon 4 in Spanish gypsies or mutations
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in exons 13, 36, and 38) have been observed in FA-A patients,
FANCA mutations are generally private mutations, which include
point mutations, microinsertions, microdeletions, splicing mutations
and large intragenic deletions (Castella et al, 2011). Thus, consider-
ing the large number of genes and mutations that can account for
the FA disease, the insertion of a functional FA gene in a ‘safe
harbor’ locus would lead to the generation of a targeted gene addi-
tion platform with a broad application in FA, regardless of the
complementation group and mutation type of each patient.
Recent studies by our group and others aiming at the identifica-
tion of ‘safe harbor sites’ in the human genome have shown robust
and stable expression of transgenes integrated in the human
PPP1R12C gene, a locus also known as AAVS1, across different cell
types (Smith et al, 2008; Lombardo et al, 2011). Additionally, no
detectable transcriptional perturbations of the PPP1R12C and its
flanking genes were observed after integration of transgenes in this
locus, indicating that AAVS1 may represent a safe landing path for
therapeutic transgene insertion in the human genome (Lombardo
et al, 2011). These observations, together with the development of
artificial zinc finger nucleases (ZFNs) that efficiently and selectively
target the AAVS1 locus, have facilitated gene editing strategies
aiming at inserting therapeutic transgenes in this locus, not only in
immortalized cell lines but also in several primary human cell types,
including induced pluripotent stem cells (hiPSCs; Hockemeyer et al,
2009; DeKelver et al, 2010; Lombardo et al, 2011; Zou et al, 2011b;
Chang & Bouhassira, 2012).
Because a defective FA pathway not only predisposes FA patients
to cancer (Rosenberg et al, 2008) but also to the early development of
bone marrow failure due to the progressive extinction of the HSCs
(Larghero et al, 2002; Jacome et al, 2006), our final aim in these stud-
ies was the generation of gene-edited, disease-free FA-HSCs, obtained
from non-hematopoietic tissues of the patient. Thus, in our current
studies, we firstly pursued the specific insertion of the therapeutic
FANCA gene in the AAVS1 locus of FA-A patients’ fibroblasts. There-
after, gene-edited FA cells were reprogrammed to generate self-
renewing disease-free iPSCs and finally re-differentiated toward the
hematopoietic lineage, as previously described with FA cells corrected
by conventional LV-mediated gene therapy (Raya et al, 2009).
Our goal of conducting a combined approach of gene editing and
cell reprogramming in FA cells was particularly challenging taking into
account the relevance of the FA pathway both in HDR (Taniguchi
et al, 2002; Yamamoto et al, 2003; Niedzwiedz et al, 2004; Yang et al,
2005; Moldovan & D’Andrea, 2009; Kee & D’Andrea, 2010;
Nakanishi et al, 2011; Kottemann & Smogorzewska, 2013) and cell
reprogramming (Raya et al, 2009; Muller et al, 2012; Yung et al,
2013). In spite of these hurdles, the strong selective growth advan-
tage characteristic of corrected FA cells allowed us to establish a new
approach for the efficient generation of FA HPCs harboring specific
integrations of the therapeutic FANCA gene in a safe harbor locus.
Results
Efficient gene-targeting-mediated complementation of
fibroblasts from FA-A patients
To promote insertion of a FANCA expression cassette into the
AAVS1 locus, an integrase-defective lentiviral vector (IDLV) harboring
the EGFP and FANCA transgenes flanked by AAVS1 homology arms
(donor IDLV) was generated (Fig 1A top). In this donor IDLV,
FANCA is under the transcriptional control of the human PGK
promoter. In addition, a promoterless EGFP cDNA preceded by a
splice acceptor (SA) site and a translational self-cleaving 2A
sequence was also included upstream of the FANCA cassette. Upon
targeted-mediated insertion into AAVS1, the EGFP cassette will be
placed under the transcriptional control of the promoter of the ubiq-
uitously expressed PPP1R12C gene, thus allowing the FACSorting of
gene-targeted cells (Fig 1A). Besides the donor IDLV, an adenoviral
vector expressing a ZFN pair (AdV5/35-ZFN), designed to induce a
DNA double-strand break in the AAVS1 locus, was used to enhance
the efficiency of gene targeting in this locus (Hockemeyer et al,
2009).
To investigate the feasibility of performing gene targeting in FA-
A cells, skin fibroblasts from four FA-A patients with different muta-
tions in FANCA were transduced either with the donor IDLV alone,
or with the donor IDLV and the AdV5/35-ZFNs simultaneously.
Fourteen days after transduction, cells were analyzed by flow
cytometry to measure the proportion of EGFP+ fibroblasts. While
<0.05% of the cells transduced with the donor IDLV alone were
positive for EGFP, 0.2–1.1% of FA fibroblasts that had been co-
transduced with the donor IDLV and the ZFNs-AdV were EGFP+
(See Fig 1B and representative analyses in Supplementary Fig S1).
Strikingly, the percentage of EGFP+ cells markedly increased during
the in vitro culture of these cells, reaching levels between 5.5 and
13.4% (Fig 1B), showing the proliferation advantage of gene-edited
FA-A fibroblasts.
Because the prolonged in vitro culture of FA fibroblasts results in
increased rates of cell senescence (Muller et al, 2012), in a new set
of experiments, fibroblasts from three FA patients (FA-52, FA-123
and FA-644) were transduced with an excisable hTERT-expressing
LV (Salmon et al, 2000) prior to performing the gene-targeting
procedure. Transduction of FA fibroblasts with hTERT-LVs resulted
in a marked increase in telomerase activity (see representative data
in Supplementary Fig S2). Significantly, the proportion of EGFP+
cells was markedly increased (3–4-fold) in hTERT-transduced versus
untransduced FA fibroblasts from FA patients (Fig 1C), indicating
that hTERT improved the efficacy of gene targeting in FA-A fibro-
blasts. Consistent with data obtained with non-immortalized fibro-
blasts, when immortalized gene-edited FA fibroblasts were
maintained in culture, a progressive increase in the proportion of
EGFP+ cells was also observed (see data from geFA-52T in Fig 1D).
Strikingly, around 40% of treated FA-A fibroblasts were EGFP+
after 42 days in culture in the absence of any selectable drug
(Fig 1D).
PCR analyses with two pairs of primers that amplify, respec-
tively, the 50 and the 30 integration junctions between the EGFP/
FANCA cassette and the endogenous AAVS1 locus evidenced the
insertion of the EGFP/FANCA cassette into the AAVS1 locus of
sorted EGFP+ geFA-52T fibroblasts (Fig 1E). In these gene-edited
FA fibroblasts, the activity of hTERT was also confirmed (Supple-
mentary Fig S2).
To investigate whether the insertion of the therapeutic hFANCA
cassette in the AAVS1 locus of FA-A fibroblasts corrected the cellu-
lar phenotype of the disease, the functionality of the FA pathway in
FA-52T fibroblasts was tested both before (negative control) and
after the gene-targeting procedure. As a positive control, healthy
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Figure 1. Efficacy of gene targeting of FANCA in the AAVS1 locus of primary hFA-A fibroblasts.
A Top: schematic representation of the donor integrase-defective lentiviral vector (IDLV) used to promote insertion of the EGFP/FANCA cassette into the AAVS1 locus.
Middle: AAVS1 locus with the zinc finger nucleases (ZFNs) target site. Bottom: AAVS1 locus upon ZFN-mediated targeted insertion of the EGFP/PGK-FANCA cassette.
Black arrow shows transcription of the EGFP from the endogenous PPP1R12C promoter. HA, homology arm; SD, splice donor; SA, splice acceptor; BGHpA, bovine
growth hormone polyadenylation signal; SV40pA, simian virus 40 polyadenylation signal. Constituents of the LTR (U5-R-DU3) are also indicated.
B Proliferation advantage of targeted Fanconi anemia (FA) fibroblasts (EGFP+ cells) during in vitro incubation.
C Comparative analysis of gene targeting in FA-A fibroblasts, untransduced or transduced with a lentiviral vector expressing hTERT. Analyses were performed 14 days
after gene targeting.
D In vitro proliferation advantage of targeted FA fibroblasts (EGFP+) previously transduced with hTERT (FA-52T fibroblasts).
E Targeted integration analysis of the EGFP/PGK-FANCA cassette into the AAVS1 site by PCR using primers specific for the 50 or 30 integration junctions (red arrows in the
top schematic) defined as 50 TI or 30 TI, respectively.
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donor fibroblasts (H.D. Fib) were analyzed in parallel. The presence
of nuclear FANCD2 foci, fully dependent on the expression of all the
FA core complex proteins, including FANCA (Garcia-Higuera et al,
2001), was determined in these samples after DNA damage induced
by mitomycin C (MMC). In contrast to uncorrected FA-52T fibro-
blasts (FA-52T Fib.), which did not generate FANCD2 foci even after
MMC exposure, a significant proportion of the geFA-52T fibroblasts
generated FANCD2 foci, mainly after treatment with MMC, thus
mimicking the response of H.D. fibroblasts (Fig 2A). Because the
main characteristic of FA cells is the increased chromosomal
instability upon exposure to DNA inter-strand cross-linking (ICL)
drugs, we also investigated the response of both uncorrected and
gene-edited FA-A fibroblasts to diepoxybutane (DEB). While in
FA-52T fibroblasts DEB induced a significant increase in the number
of chromosomal aberrations per cell (from 0.05  0.05 to
1.7  0.46 aberrations/cell)— including chromatid breaks and
A
geFA-52T Fib.H.D. Fib.
+ 
M
M
C
FANCD2FANCD2
B
+ 
D
EB
-D
EB
- +-+DEB
geFA-52T Fib.FA-52T Fib. 
FA-52T Fib. geFA-52T Fib.
FA-52T Fib. 
0
5
10
15
20
25
30
35
Fib. H.D Fib. FA-52T geFib. FA-52T
%
 o
f c
el
ls
 w
ith
 F
AN
C
D
2 
fo
ci
- MMC
+ MMC
FANCD2
0
0.5
1
1.5
2
2.5
N
er
of
 a
be
rr
at
io
ns
/ c
el
l
p=0.001
p=0.29
%
 o
f c
el
ls
 w
ith
 F
AN
C
D
2 
fo
ci
-
 
p= 0.003
p= 0.87
p= 0.0001
H.D. Fib.                 FA-52T Fib.           geFA-52T Fib.
Figure 2. Phenotypic correction of the gene-edited FA-A fibroblasts.
A Top: histogram showing the percentage of FA-A fibroblasts, unstransduced or co-transduced with the donor integrase-defective lentiviral vector (IDLV) and the AdV5/
35-ZFNs (geFA-52T Fib), showing FANCD2 foci in the absence or the presence of mitomycin C (MMC). Bottom: representative images of FANCD2 foci (red) in cells
shown in the top histogram, after MMC treatment.
B Chromosomal instability induced by diepoxybutane (DEB) in untreated (FA-52T) and gene-edited FA fibroblasts (geFA-52T Fib). Left: representative FISH analysis was
performed by staining telomeres (in green), centromeres (in pink) and chromosomes (in blue). Right: histogram showing the number of chromosomal aberrations per
cell.
Data information: Values are shown as mean  s.e. from three independent experiments (A) or analysis of twenty different metaphases per group (B). All P-values were
calculated using two-tailed unpaired Student’s t-test.
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radial chromosomes, typically found in FA patients0 cells—the same
DEB treatment did not induce any increase in the number of chro-
mosomal aberrations in geFA-52T fibroblasts (Fig 2B).
Taken together, these results show the feasibility of correcting
the phenotype of FA cells using gene targeting strategies, in particu-
lar by promoting the insertion and expression of FANCA in the
AAVS1 safe harbor locus of fibroblasts from FA-A patients.
Efficient generation of disease-free iPSCs from FA fibroblasts
corrected by gene targeting
To generate disease-free FA-iPSCs, FA fibroblasts subjected to gene
editing (geFA-123, geFA-52 and geFA-52T) were first enriched for
EGFP+ cells by cell sorting and then reprogrammed using a poly-
cistronic excisable LV expressing the human SOX2, OCT4, KLF4,
and cMYC transgenes from the EF1A promoter (STEMCCA vector;
Somers et al, 2010). Consistent with previous observations (Raya
et al, 2009), uncorrected FA fibroblasts did not generate iPSCs after
reprogramming, even after transduction with the TERT-LV (data
not shown). Although several iPSC-like colonies were generated
from gene-edited FA-123 fibroblasts (115 AP+ cells/100,000 fibro-
blasts), no stable iPSC lines could be generated from FA fibroblasts
simply subjected to gene editing, most probably because of the
pro-senescence nature of these cells. In marked contrast to these
observations, the reprogramming of FA fibroblasts that were first
transduced with the hTERT-LV and then subjected to gene editing
generated 230 iPSC-like clones, most of which could be maintained
after serial in vitro passages (Supplementary Fig S3). Twelve iPSC
clones generated from geFA-52T fibroblasts were further expanded
and differentiated into fibroblasts to perform additional studies to
confirm the integration site of the EGFP/FANCA construct. First,
qPCR analyses were conducted to determine the mean copy
number per cell of the EGFP/FANCA cassette. As shown in Supple-
mentary Table S1, 11 out of the 12 geFA-iPSC clones analyzed
were positive for EGFP integration and contained an average of
0.98  0.44 EGFP copies per cell. The only iPSC clone that did not
harbor any EGFP copy (clone 5) did not progress more than six
passages in culture.
To investigate whether the EGFP/FANCA cassette was specifically
integrated in the AAVS1 locus of all these iPSC clones, 30 primers
previously used in analyses of Fig 1E were used. As shown in
Supplementary Table S1, all iPSC clones that were positive for inte-
gration of the cassette were also positive for the PCR band corre-
sponding to the specific insertion in the AAVS1 locus.
Three geFA-iPSC clones (clones 16, 26 and 31) were selected
for further characterization. The pluripotency of these gene-
corrected clones was first analyzed both by alkaline phosphatase
(AP) staining and immunohistochemistry staining of different
pluripotency genes. Representative pictures in Fig 3A and Supple-
mentary Fig S4A showed that all tested geFA-iPSCs clones were
highly positive for AP, NANOG, TRA-1-60, OCT4, and SSEA-4
expression. RT-qPCR analyses of the expression of endogenous
pluripotency genes NANOG, OCT4, SOX2, KLF4, and cMYC were
consistent with the pluripotent nature of these clones (Supplemen-
tary Fig S4B). In all cases, a very low expression of the ectopic
reprogramming transgenes was found, indicating substantial
inactivation of the EF1A promoter present in the reprogramming
vector. As expected for bona fide iPSC clones, OCT4 and NANOG
promoters were hypomethylated in gene-corrected FA-iPSC clones,
in clear contrast to the high level of methylation observed in H.D.
fibroblasts (Supplementary Fig S4C). To further demonstrate the
pluripotency of geFA-iPSC16 cells in vivo, cells were subcutane-
ously inoculated in NSG mice. Characteristic teratomas containing
complex structures representing the three embryonic germ layers
were observed 8–10 weeks after implantation. Immunofluores-
cence staining confirmed the expression of definitive endoderm
markers (Fox2A), neural structures that expressed neuroectoder-
mal markers (ß-III-tubulin) and the generation of mesoderm
(Brachyury) and mesoderm derivatives tissue such as muscle
(a-SMA; Fig 3B).
To confirm the insertion of the FANCA cassette into the AAVS1
locus in the gene-corrected FA-iPSC clones, Southern blot analyses
were performed on genomic DNA extracted from gene-edited geFA-
iPSC clones 16, 26, and 31. Blots hybridized with probes for the
exogenous EGFP and the endogenous AAVS1 genes confirmed the
monoallelic integration of the EGFP/FANCA cassette into the AAVS1
locus and the absence of random integration in any of the three
tested clones (Fig 3C,D).
Once demonstrated the generation of bona fide gene-edited FA-
iPSCs, in the next set of experiments, we aimed to verify whether
these geFA-iPSCs were disease free, as shown for their parental
gene-edited FA fibroblasts (Fig 2). First, we verified by qRT-PCR
that hFANCA mRNA levels corresponding to the three tested geFA-
iPSC clones were very similar to levels observed in the control ES
cell line and markedly higher when compared to uncorrected FA-
52T fibroblasts (Fig 4A). Western blot analysis confirmed the
expression of FANCA in all the three tested clones (Fig 4B). Even
more, since FANCA is necessary for the relocation of FANCD2 to
damaged DNA sites, we investigated the presence of nuclear
FANCD2 foci in three geFA-iPSC clones exposed to MMC. As shown
in Fig 4C, these analyses further confirmed the expression and func-
tionality of FANCA in the three tested geFA-iPSC clones. Consistent
with the restored FA pathway of gene-edited FA-iPSCs, DEB did not
induce a significant increase in the number of chromosomal aberra-
tions in FA-corrected cells. Remarkably, the number of chromo-
somal aberrations in geFA-iPSCs (0.2  0.1 aberrations/cell;
Fig 4D) was ten times lower to the number observed in their paren-
tal uncorrected fibroblasts (see Fig 2B).
To assure the identity of the different geFA-iPSC clones, the
presence of the original pathogenic mutations described in patient
FA-52 (c.710-5T>C and c.3558insG) was investigated by Sanger
sequencing both on FA-52T fibroblasts and geFA-iPSC clones 16, 26,
and 31 (Supplementary Fig S5). The confirmation of both patho-
genic mutations in the three tested geFA-iPSCs, together with our
observations showing that all stable iPSC clones contained the
AAVS1-targeted FANCA gene (Supplementary Table S1) and had a
functional FA pathway, demonstrates that the disease-free nature of
gene-edited FA-iPSCs is a consequence of the functional insertion of
FANCA within the AAVS1 safe harbor site of these reprogrammed
FA cells.
Aiming to excise the STEMCCA vector from the genome of
geFA-iPSCs, cells from clone 16 were transduced with an IDLV
co-expressing the Cre recombinase and the Cherry fluorescence
marker (Papapetrou et al, 2011). Thereafter, individual colonies
were isolated to select those clones with a lower number of copies
of the STEMCCA provirus. Two clones were selected: Excised clones
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Figure 3. Pluripotency characterization and insertion site analyses of gene-edited FA-A iPSCs.
A Expression of TRA1-60, SSEA-4, OCT4, and NANOG pluripotency markers by immunofluorescence staining of gene-edited FA-iPSCs (geFA-iPSCs; clone 16).
B Immunofluorescence analysis of ectoderm (b-II-tubulin), endoderm (Fox2A), and mesoderm (a-SMA and Brachyury) in teratomas generated from geFA-iPSCs
(clone 16).
C Southern blot analysis of genomic DNA extracted from the indicated gene-corrected FA iPSC clones (geFA-IPSCs) and from parental fibroblasts, either unmanipulated
(FA) or after gene editing (ge-FA iPSCs, clones 16, 26 and 31). Genomic DNA was digested with BglI and hybridized with a probe for PPP1R12C. The band of 9.6 kb
corresponds to the targeted integration in PPP1R12C, while the 3.3 kb correspond to the untargeted allele.
D Southern blot analysis of samples shown in (C) digested with BstXI and hybridized with a probe (P) for EGFP. One single band of 5.1 kb is expected for specific
integrations in PPP1R12C.
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16.1 and 16.2, with a number of 0.35  0.10 and <0.05 copies/cell,
respectively. In clone 16.2, the excision of the hTERT provirus was
also confirmed (<0.05 copies as deduced from q-PCR analyses).
RT-qPCR analysis performed in these two subclones showed the
persistent expression of endogenous pluripotency genes (SOX2,
OCT4, KLF4, NANOG, and cMYC) and the absence of ectopic transg-
enes expression (Supplementary Fig S6A). As expected from bona fide
pluripotent iPSC clones, these two clones generated teratomas with
structures characteristics of the three germ layers (Supplementary
Fig S6B).
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Figure 4. Disease-free Fanconi anemia phenotype of corrected geFA-iPSCs.
A Histogram showing the levels of hFANCA expression in gene-edited FA-iPSC clones and human ES (H9) relative to untreated FA-52T fibroblasts. Data are shown as
mean  s.e. of three different analyses.
B Western blot analysis showing FANCA expression in geFA-iPSC clones in comparison with fibroblasts from HD and a FA-A patient.
C Representative immunofluorescence analysis of FANCD2 foci in geFA-iPSCs after DNA damage with mitomycin C (MMC).
D Chromosomal instability induced by diepoxybutane (DEB) was also tested in geFA-iPSC 16. FISH analysis was performed using probes to detect telomeres (green),
centromeres (pink) and chromosomes (blue). Right: histogram showing the number of chromosomal aberrations per cell.
Data information: Data are shown as mean  s.e. from three different experiments (A) or analysis of twenty different metaphases per group (D). All P-values were
calculated using two-tailed unpaired Student’s t-test.
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Analysis of the genetic stability of gene-edited FA fibroblasts
and iPSCs
Because of the chromosomal instability of FA cells, we investigated
by means of karyotype analyses and aCGH analyses whether the
different manipulations of FA-52 fibroblasts and their corresponding
iPSCs induced chromosomal instability. As shown in Table 1, no
evident karyotype or aCGH abnormalities were observed in
expanded FA-52 parental fibroblasts when compared with a
reference human DNA sample. Even more, the transduction with
hTERT-LV and the gene-editing process did not induce evident
chromosomal abnormalities in these cells. Reprogrammed geFA-52
iPSCs also had a normal karyotype, although a deletion in the
16p12.2p12.1 locus was noted in the aCGH analysis. After excision
with the Cre recombinase, in addition to the 16p deletion, a mosaic
trisomy in chromosome 5 was observed (See Table 1 and Supple-
mentary Fig S7).
Generation of disease-free hematopoietic progenitors from
gene-edited FA-A iPSCs
In experiments corresponding to Fig 5 and Supplementary Figs S8
and S9, we investigated whether hematopoietic progenitor cells
derived from gene-edited FA-iPSCs were disease-free. To conduct
these experiments, embryoid bodies from geFA-iPSCs were incu-
bated with hematopoietic cytokines as described in Materials and
methods. As shown in representative analyses from Supplementary
Fig S8A, the hematopoietic differentiation of geFA-iPSCs after
21 days of in vitro stimulation was demonstrated by the presence of
hematopoietic precursors (CD43+/CD34+), committed hematopoi-
etic progenitors (CD34+/CD45+) and also mature hematopoietic
cells (CD34/CD45+). When the hematopoietic differentiation of
excised and non-excised iPSC clones was compared, the proportion
of CD45+ and CD34+/CD45+ was consistently increased in the case
of the excised vs the non-excised clones (see data from two indepen-
dent experiments in Fig 5A and Supplementary Fig S8). Consistent
with the flow cytometry data, granulo-macrophage and erythroid
colonies were generated by geFA-iPSC-differentiated cells in methyl-
cellulose. As it was observed in the flow cytometry studies, higher
numbers of hematopoietic progenitors were generated by excised
versus non-excised geFA-iPSC (Fig 5B). In all instances, colonies
derived from geFA-iPSC were almost as resistant to MMC as healthy
cord blood progenitor cells, in contrast to the MMC hypersensitivity
observed in BM progenitors from FA patients (Fig 5C).
Finally, to investigate whether gene-edited FA-iPSCs were also
able to differentiate toward the hematopoietic lineage in vivo, one of
the teratomas generated by the excised geFA-52 iPSCs (clone 16.2)
was analyzed for the presence of human hematopoietic markers. As
shown in Supplementary Fig S9, 3% of the cells present in this tera-
toma consisted on hCD45+/mCD45 cells. Within this population,
3.5% corresponded to hCD34+ cells, thus revealing the in vivo
differentiation potential of this clone.
Discussion
Thanks to the development of artificial nucleases capable of generat-
ing DNA double-strand breaks (DSBs) in pre-determined sequences
of the genome (Porteus & Baltimore, 2003; Urnov et al, 2010; Cong
et al, 2013; Joung & Sander, 2013), targeted gene therapy is entering
into the clinics (Tebas et al, 2014). Whether these approaches will
be amenable to the treatment of DNA repair deficiency syndromes
such as FA is, however, uncertain. In this respect, it is currently
known that FA proteins participate in maintaining the genomic
stability of the cell and coordinate the actions of multiple repair
processes, including HDR (Kottemann & Smogorzewska, 2013),
making these cells particularly appropriate for investigating the
feasibility of performing targeted gene therapy in syndromes associ-
ated with DNA repair defects and genome instability. Although the
mechanisms explaining how the FA pathway promotes HDR are still
unclear, most evidence suggests that the monoubiquitination of
FANCD2—which is critically dependent on the presence of all the
FA core complex proteins, including FANCA—is essential for the
recruitment of several HDR factors (such as BRCA1, BRCA2, and
RAD51) to damaged chromatin (see review in Kee & D’Andrea,
2010).
To investigate whether gene targeting was feasible in FA cells we
focused on the most frequent FA complementation group, FA-A
(Casado et al, 2007; Auerbach, 2009), and investigated the possibil-
ity of inserting the therapeutic transgene in a safe harbor locus of
the human genome—the AAVS1 locus (Lombardo et al, 2011).
Strikingly, our first results in Fig 1 clearly demonstrate the
feasibility of performing gene targeting in FA-A cells with signifi-
cant efficacies (up to 4%), comparable with efficacies reported in
primary cells competent for DNA repair (DeKelver et al, 2010;
Lombardo et al, 2011; Sebastiano et al, 2011; Soldner et al, 2011;
Zou et al, 2011a). The feasibility of performing gene targeting in
FA-A cells could be explained by different hypotheses. First, as
previously described in other systems (Matrai et al, 2011; Peluffo
et al, 2013), a transient though early expression of FANCA may be
induced by the donor IDLV, thus facilitating the insertion of the
exogenous therapeutic cassette through a HDR process. Besides
Table 1. aCGH analysis in FA-52 fibroblasts prior to and after gene
editing and in gene-edited IPSCs-derived clones
Cells
aCGH result
KaryotypeAlteration Locus
OMIM
GENES
FA-52
fibroblastsa
– – – 46 XY
geFA-52T fibr.b – – – 46 XY
geFA-52T iPSC clones
Clone 16c Deletion 16p12.2p12.1 * 46 XY
Clone 16 Exc Deletion 16p12.2p12.1 * 46 XY
Mosaic
trisomy
5 – 46 XY
*EEF2K, CDR2, HS3ST2, SCNN1G, SCNN1B, COG7, GGA2, EARS2, NDUFAB1,
PALB2, DCTN5, PLK1, ERN2, PRKCB, CACNG3, RBBP6.
aComparison analyses between expanded fibroblasts from patient FA-52 (FA-
52 fibroblasts) and a reference male DNA sample.
bComparison analyses between expanded, TERT-transduced, and gene-edited
FA-52 fibroblasts (geFA-52T fibr.) with respect to FA-52 fibroblasts.
cComparison analyses between geFA-52T iPSCs clone 16 and clone 16 Ex
(after excision of the reprogramming cassette) and FA-52 fibroblasts.
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this hypothesis, we should contemplate the possibility that the
limited HDR activity of FA-A cells (Nakanishi et al, 2005, 2011)
could be sufficient to facilitate the ZFN-mediated integration of
our donor IDLV in the AAVS1 site. Finally, although the integra-
tion of the therapeutic cassette in the AAVS1 locus might have
occurred through an HDR-independent process, as reported in
other models (Anguela et al, 2014), PCR and Southern blot analy-
ses showed the expected amplicons and band length for targeted
BFU-ES
CFU-GMs
A
0
2
4
6
8
10
12
14
16
CD34+CD43+ CD34+CD45+ CD45+
%
 p
os
iti
ve
 c
el
ls
geFA-iPSC 16.1 Ex
geFA-iPSC16
B
0
20
40
60
80
100
geFA-iPSC16 H.D. CB FA-664 BM FA-82 BM
C
FC
s
su
rv
iv
al
(%
)
- MMC
+ MMC
1
10
100
1000
geFA-IPSC16 geFA-iPSC16 Ex H.D. CB
N
er
of
 C
FC
s/
1x
10
5
ce
lls p= 0.04
p= 0.2
p= 0.019
C
Figure 5. Hematopoietic differentiation of gene-edited FA-IPSCs.
A Analysis of the percentage of CD43+CD34+, CD45+CD34+, and CD45+ cells generated by unexcised and excised geFA-iPSCs (clones 16 and Ex 16.1).
B Left: Representative pictures of hematopoietic colonies generated by geFA-iPSCs. Right: Analysis of the clonogenic potential of unexcised and excised ge-FAiPSCs
(clones 16 and Ex 16.1) in comparison with H.D. cord blood cells.
C Survival to mitomycin C (MMC) of CFCs obtained from geFA-IPSCs (clone 16) in comparison with BM CFCs from two different FA patients (FA-664 BM and FA-82 BM)
and with CFCs from a healthy cord blood (H.D. CB).
Data information: Values are shown as mean  s.e. of three experiments. All P-values were calculated using two-tailed unpaired Student’s t-test.
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integration of the cassette, strongly suggesting that AAVS1 target-
ing took place through a HDR mechanism. In this respect, while
the specificity of gene targeting might be reduced in FA cells, our
data clearly show that all the FA-iPSC clones harbored one single
copy of FANCA specifically integrated in the PPPR12C target gene
(Table 1). Consequently, this result further supports the efficacy
and the specificity of our gene targeting approach.
With the main objective of preventing the predisposition to
senescence of FA cells (Muller et al, 2012), the transduction of
hTERT-LV in FA-A fibroblasts induced an unexpected effect in these
cells, which consisted of a significant increase in the efficacy of gene
editing (Fig 1). Whether or not this effect is specific for FA cells or
whether it is simply mediated by the enhanced proliferation rate of
TERT-transduced FA cells is currently unknown. Nevertheless, to
the best of our knowledge, the improved gene targeting mediated by
hTERT observed in our experiments constitutes a new finding that
has not been previously reported in any other experimental model.
The observation that transduction with hTERT also facilitates the
generation of gene-edited FA-iPSCs is consistent with previous data
showing the relevance of hTERT in cell reprogramming (Batista
et al, 2011; Pomp et al, 2011; Winkler et al, 2013). In safety terms,
even though the hTERT provirus could be efficiently excised from
transduced cells with the Cre recombinase, further approaches
based on the transient expression of hTERT during gene editing
and/or cell reprogramming would constitute safer approaches to
limit potential genomic insults during the ex vivo manipulation of
the samples.
Interestingly, EGFP analyses in gene-edited FA fibroblasts
showed that in the absence of any artificial selection process, a
progressive increase in the proportion of targeted cells (up to 40%
after 42 days in culture) was observed, mimicking the improved
growth proliferation properties of FA precursor cells in mosaic
patients (Waisfisz et al, 1999; Gregory et al, 2001; Gross et al,
2002) or in experimental models of FA gene therapy (Rio et al,
2008). Consistent with previous observations in FA cells corrected
by LV-mediated gene therapy (Raya et al, 2009), this proliferation
competence of FA-corrected cells was particularly remarkable when
samples were subjected to cell reprogramming, confirming the rele-
vance of the FA pathway during the process of iPSC generation.
Similar conclusions were obtained in two additional studies (Muller
et al, 2012; Yung et al, 2013), although these studies showed that
reprogramming of FA cells can occur, albeit with a very low effi-
ciency compared to gene-complemented FA cells.
Studies in Figs 2 and 4 showing the generation of nuclear
FANCD2 foci and the chromosomal stability of gene-edited FA
fibroblasts and iPSCs upon exposure to ICL drugs demonstrate
that the specific targeting of FANCA in the AAVS1 locus has
completely corrected the phenotype of FA-A fibroblasts and bona
fide iPSCs. Although transduction of FA fibroblasts with the
hTERT-LV might have had consequences upon the genetic insta-
bility of FA cells, our karyotype and aCGH studies indicate that
neither the expansion nor the transduction with hTERT-LV or the
gene-editing processes induced evident chromosomal abnormali-
ties in FA fibroblasts. In contrast to these results, data in Table 1
and Supplementary Fig S7 showed the presence of chromosomal
abnormalities in reprogrammed and excised geFA-iPSCs. Impor-
tantly, different genetic defects have also been reported in non-
FA-iPSCs (Mayshar et al, 2010; Gore et al, 2011; Laurent et al,
2011; Cheng et al, 2012; Ruiz et al, 2013) that were associated
with the generation of the iPSCs (Mayshar et al, 2010; Gore et al,
2011; Hussein et al, 2011; Laurent et al, 2011) and/or with muta-
tions that pre-existed in the somatic population of origin (Young
et al, 2012). This indicates that the presence of chromosomal
abnormalities in our iPSCs is not exclusive of their FA genetic
background and that the different mechanisms accounting for
mutations in non-FA-iPSCs would be applicable to our geFA-
iPSCs.
Consistent with the previous study showing the generation of
disease-free FA-iPSCs through conventional gene therapy
approaches (Raya et al, 2009; Muller et al, 2012), our new study
shows the efficient hematopoietic differentiation of gene-edited FA-
iPSCs. Moreover in the current study, we observed the generation of
increased numbers of hematopoietic progenitors from geFA-iPSCs
subjected to excision of the reprogramming cassette, confirming
previous observations showing that the residual expression of repro-
gramming genes limits the iPSC differentiation potential (Ramos-
Mejia et al, 2012). The hematopoietic differentiation observed in
these experiments and the robust expression of FANCA targeted into
the safe harbor AAVS1 locus should account for the generation of a
high number of hematopoietic progenitors with normalized
response to MMC.
In summary, our study demonstrates for the first time the possi-
bility of conducting efficient and precise targeted-mediated gene
therapy in HDR-deficient cells. Moreover, we show the feasibility of
reprogramming these cells to generate iPSC-derived gene-edited
hematopoietic progenitors characterized by a disease-free pheno-
type. Our approach thus constitutes a new proof-of-concept with a
potential future clinical impact to optimize the generation of gene-
corrected HSCs from non-hematopoietic tissues of patients with
inherited diseases, including DNA repair deficiency and genetic
instability syndromes, like FA.
Materials and Methods
Cell lines and primary fibroblasts from FA-A patients
293T and HT1080 cells (ATCC: CRL-11268 and ATCC: CCL-121)
were used for the production and titration of the LVs, respec-
tively. Cells were grown in Dulbecco’s modified medium
GlutaMAXTM (DMEM; Gibco) supplemented with 10% fetal bovine
serum (FBS, Biowhitaker) and 0.5% penicillin/streptomycin solu-
tion (Gibco). Skin fibroblasts were obtained from FA-5, FA-123,
FA-664, and FA-52 patients and were maintained in DMEM (Invi-
trogen) supplemented with 20% FBS (Biowhitaker) and 1% peni-
cillin/streptomycin solution (Gibco) at 37°C under hypoxic
conditions (5% of O2) and 5% of CO2. Patients were classified as
FA-A patients as previously described (Casado et al, 2007). The
ES4 and H9 (NIH Human Embryonic Stem Cell Registry, http://
stemcells.nih.gov/research/registry/) lines of hES cells were main-
tained as originally described (Raya et al, 2008). FA patients and
healthy donors were encoded to protect their confidentiality, and
informed consents were obtained in all cases according to Institu-
tional regulations of the CIEMAT. All studies conformed the prin-
ciples set out in the World Medical Association Declaration of
Helsinki.
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Vectors
pCCL.sin.cPPT.AAVS1.loxP.SA.2A.GFP.pA.loxP.PGK.FANCA.pA.Wpre
donor transfer LV (donor IDLV) was generated using elements
from the backbones pCCL.PGK.FANCA.Wpre* (Gonzalez-Murillo
et al, 2010) and pCCLsin.cPPT.AAVS1.2A.GFP.pA (Lombardo
et al, 2011). The integrase-defective third-generation packaging
plasmid pMD.Lg/pRRE.D64Vint was used to produce IDLV parti-
cles (Lombardo et al, 2007). pLM.CMV.Cherry.2A.Cre (Papapetrou
et al, 2011) and pLox.TERT.ires.TK vectors (Salmon et al, 2000)
were provided by Addgene. For reprogramming experiments,
the EF1a STEMCCA lentiviral vector kindly provided by
Dr Mostoslavsky was used (Sommer et al, 2010). This vector
contains the cDNAs for OCT4, SOX2, c-MYC, and KLF4 flanked by
loxP sequences for their subsequent excision. ZFNs targeting
intron 1 of the PPP1R12C gene were expressed from an Adenoviral
Vector (AdV5/35) under the control of the CMV promoter (Lom-
bardo et al, 2011).
Cell transduction
For gene editing experiments, fibroblasts from FA-A patients were
transduced either with donor IDLV alone (150 ng HIV Gag p24/ml)
or together with AdV5/35-ZFNs (multiplicity of infection (MOI)
200). Fourteen days post-transduction, the proportion of EGFP+
cells was determined by flow cytometry (BD LSRFortessa cell
analyzer, Becton Dickinson Pharmingen). To immortalize fibro-
blasts from FA-52 to FA-123 patients, 105 cells were transduced at
MOI 1 with the pLox.TERT.ires.TK LV (Salmon et al, 2000) for
24 h. To excise the reprogramming cassette and hTERT from estab-
lished hiPSCs, single cell suspensions were generated by incubation
with accutase (Gibco) and transduced for 10 h with the IDLV
pLM.CMV.Cherry.2A.Cre. Immediately after transduction,
2 × 104 cells/10 cm2 dish, expressing Cherry protein, were sorted
and new subclones of the parental geFA-IPSCs were generated.
Hematopoietic differentiation
iPSC colonies were detached using colagenase type IV (Gibco) for
30 min at 37°C, washed and centrifuged at 200× g, resuspended in
differentiation media composed by KO-DMEM (Gibco) supple-
mented with 20% non-heat-inactivated FBS (Biowhitaker), 1%
NEAA (Lonza; Biowhitaker), L-Glu (1 mM; Invitrogen), b-mercap-
toethanol (0.1 mM; Gibco) and hrBMP4 (0.5 ng/ml; Prepotech)
and plated in ultra-low attachment plates (Costar). After 2 days,
media were replaced by Stempro 34 (Invitrogen) supplemented
with 0.5% pen/streptomicin, L-Glu (2 mM; Invitrogen), MTG
(40 mM; Sigma), ascorbic acid (50 lg/ml; Invitrogen), hrSCF,
hrFlt3 ligand and TPO (100 ng/ml; EuroBioSciences), hrIL3
(10 ng/ml; Biosource), hrIL6 (10 ng/ml; Prepotech), hrBMP4
(50 ng/ml; Prepotech), Wnt11 (200 ng/ml; R&D), and rhVEGF
(5 ng/ml; Prepotech). Media were changed every 3–4 days. At
day 7, media were replaced by fresh media where rhWnt-11 was
substituted by rhWnt-3a (200 ng/ml; R&D). Media were changed
every 3–4 days. At day 14 and 21, immunophenotypic analysis of
the differentiated cells was performed by flow cytometry, and
colony-forming unit assays were conducted (See Supplementary
Methods).
Flow cytometry
Transduction with the AdV5/35-ZFNs and the donor IDLV, was
analyzed by flow cytometry analysis (FACSCalibur; Becton
Dickinson Pharmingen). Immunophenotypic analysis of the hemato-
poietic differentiated cells was performed using the following anti-
bodies according to the manufacturer’s instructions: phycoerythrin
(PE)-Cy7-conjugated anti-human CD34 (BD Pharmingen), PE-conju-
gated anti-human CD31 (eBiosciences), allophycocyanin (APC)-
conjugated anti-human CD45 (BD), and fluorescein isothiocyanate
(FITC)-conjugated anti-human CD43 (BD). Fluorochrome-matched
isotypes were used as controls. 40,6-Diamidino-2-phenylindole
(DAPI; Roche)-positive cells were excluded from the analysis.
Analysis was performed using FlowJo software.
Inmunofluorescence and Western blot of Fanconi
anemia proteins
Analyses of FANCD2 foci were performed by immunofluorescence
of primary fibroblasts or iPSCs treated for 16 h with 200 nM of
MMC. After MMC treatment, cells were stained with rabbit poly-
clonal anti-FANCD2 (Abcam, ab2187-50) as previously described
(Hotta & Ellis, 2008; Raya et al, 2009). Cells with more than ten
foci were scored as positive. FANCA expression was analyzed by
Western blot (Raya et al, 2009) using the following antibodies:
hFANCA (ab5063 Abcam) and anti-beta Actin to mouse antibody
(ab6276, Abcam) as control. Goat polyclonal antibody to rabbit
IgG (HRP; ab6721-1; Abcam) and sheep polyclonal antibody to
mouse IgG—H&L (HRP; ab 6808, Abcam) were used as secondary
antibodies. Protein quantification was done with Image J soft-
ware.
FANCA expression by qRT-PCR
The expression of human FANCA mRNA was analyzed in the differ-
ent clones of geFA-iPSCs by real-time quantitative reverse transcrip-
tase-polymerase chain reaction (qRT-PCR; Gonzalez-Murillo et al,
2010) using primers described in Supplementary Methods. Parental
fibroblasts from FA-52 and ES H9 were used as controls.
Gene targeting analysis: PCR and Southern blots
For PCR analysis, genomic DNA was extracted with DNeasy Blood
& Tissue Kit (Qiagen). To detect the targeted integration of the HDR
cassette in the AAVS1 locus, two different pair of primers for the 30
or the 50 integration junction (50 TI and 30 TI, respectively) were
used (Supplementary Table S2). PCR was conducted as follows:
2 min at 94°C, 40 cycles of 30 s at 94°C, 30 s at 58°C (50 TI) and
59°C (30 TI), 1 min at 72°C and one final step for 5 min at 72°C. The
proper target integration amplified a 1195 pb amplicon for the 50 TI
and a 1314 pb fragment for the 30 TI that were resolved in agarose
gel at 2%. For Southern blot analyses, genomic DNA was extracted
and digested either with BstXI enzyme or with BglI (both from New
England Biolabs). Matched DNA amounts were separated on 0.8%
agarose gel, transferred to a nylon membrane (Hybond XL, GE
Healthcare) and probed either with the 32P-radiolabeled sequence of
a fragment of EGFP to detect specific (5.1 kb) and non-specific inte-
grations or with a probe of AAVS1 gene located outside of the
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homology arm (in the 30 region) to detect specific integration in the
proper target locus (9.6 kb) and the unmodified AAVS1 locus
(3.3 kb). To detect the radiolabel signal, auto-radiographic films
were used (Amershan Hyperfilm ECL, GE Healthcare) and they were
exposed in an automatic reveal machine Curix60 (AGFA).
Supplementary information for this article is available online:
http://embomolmed.embopress.org
Acknowledgements
The authors would like to thank Prof. Juan C. Izpisua-Belmonte and Dr Guiller-
mo Guenechea for helpful discussions; Laura Cerrato for technical assistance
with iPSCs; and Aurora de la Cal for coordination with the FA Network. We are
also indebted to the FA patients, families, and clinicians from the FA network.
This work was supported by grants to J.A.B. from the European Union (FP7 GA
222878 PERSIST), Spanish Ministry of Economy and Competitiveness (Interna-
tional Cooperation on Stem Cell Research Plan E; Ref PLE 2009/0100; SAF
2009-07164 and SAF 2012-39834), Fondo de Investigaciones Sanitarias, Institu-
to de Salud Carlos III (RETICS-RD06/0010/0015 and RD12/0019/0023), Direc-
ción General de Investigación de la Comunidad de Madrid (CellCAM; Ref
S2010/BMD-2420), and La Fundació Privada La Marató de TV3, 121430/31/32;
to J.S. from the Generalitat de Catalunya (SGR0489-2009), the ICREA-Academia
program, the Marató de TV3 (464/C/2012), the Spanish Ministry of Science and
Innovation (SAF2012-31881), the European Commission (HEALTH-F5-2012-
305421), and the European Regional Development FEDER Funds; to L.N. from
Telethon (TIGET grant D2), European Union (FP7 GA 222878 PERSIST, ERC
Advanced Grant 249845 TARGETINGGENETHERAPY) and the Italian Ministry of
Health. The authors also thank the Fundación Marcelino Botín for promoting
translational research at the Hematopoietic Innovative Therapies Division of
the CIEMAT. CIBERER is an initiative of the Instituto de Salud Carlos III, Spain.
Author contributions
Contribution: PR, RB, AL, LN, and JAB conceived and designed the experiments.
PR, RB, AL, OQ-B, LA, ZG, PG, EA, AV, BD, SN, YT, JPT, and RM conducted experi-
ments. JCS, ES, JS, PDG, and MCH provided reagents, tools, and ideas. PR, RB,
AL, LN, and JAB wrote the paper.
Conflict of interest
P.D.G. and M.C.H. are current or former employees of Sangamo BioSciences,
Inc. The rest of the authors declare that they have no conflict of interest.
For more information
Fanconi Anemia Research Foundation: www.fanconi.org.
References
Anguela XM, Sharma R, Doyon Y, Miller JC, Li H, Haurigot V, Rohde ME, Wong
SY, Davidson RJ, Zhou S et al (2014) Robust ZFN-mediated genome
editing in adult hemophilic mice. Blood 122: 3283 – 3287
Auerbach AD (2009) Fanconi anemia and its diagnosis. Mutat Res 668: 4 – 10
Batista LF, Pech MF, Zhong FL, Nguyen HN, Xie KT, Zaug AJ, Crary SM, Choi J,
Sebastiano V, Cherry A et al (2011) Telomere shortening and loss of
self-renewal in dyskeratosis congenita induced pluripotent stem cells.
Nature 474: 399 – 402
Bogliolo M, Schuster B, Stoepker C, Derkunt B, Su Y, Raams A, Trujillo JP,
Minguillon J, Ramirez MJ, Pujol R et al (2013) Mutations in ERCC4,
encoding the DNA-repair endonuclease XPF, cause Fanconi anemia. Am J
Hum Genet 92: 800 – 806
Casado JA, Callen E, Jacome A, Rio P, Castella M, Lobitz S, Ferro T, Munoz A,
Sevilla J, Cantalejo A et al (2007) A comprehensive strategy for the
subtyping of Fanconi Anemia patients: conclusions from the Spanish
Fanconi Anemia research network. J Med Genet 44: 241 – 249
Castella M, Pujol R, Callen E, Trujillo JP, Casado JA, Gille H, Lach FP,
Auerbach AD, Schindler D, Benitez J et al (2011) Origin, functional role
and clinical impact of Fanconi anemia FANCA mutations. Blood 117:
3759 – 3769
Chang CJ, Bouhassira EE (2012) Zinc-finger nuclease mediated correction of
alpha-thalassemia in iPS cells. Blood 120: 3906 – 3914
Cheng L, Hansen NF, Zhao L, Du Y, Zou C, Donovan FX, Chou BK, Zhou G, Li
S, Dowey SN et al (2012) Low incidence of DNA sequence variation in
human induced pluripotent stem cells generated by nonintegrating
plasmid expression. Cell Stem Cell 10: 337 – 344
Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W,
Marraffini LA et al (2013) Multiplex genome engineering using CRISPR/Cas
systems. Science 339: 819 – 823
DeKelver RC, Choi VM, Moehle EA, Paschon DE, Hockemeyer D, Meijsing SH,
Sancak Y, Cui X, Steine EJ, Miller JC et al (2010) Functional genomics,
proteomics, and regulatory DNA analysis in isogenic settings using zinc
finger nuclease-driven transgenesis into a safe harbor locus in the human
genome. Genome Res 20: 1133 – 1142
Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J,
Grompe M, D’Andrea AD (2001) Interaction of the Fanconi anemia
proteins and BRCA1 in a common pathway. Mol Cell 7:
249 – 262
The paper explained
Problem
Gene targeting is becoming a true alternative to conventional gene
therapy with integrative gammaretroviral or lentiviral vectors. It is
however unknown whether these approaches would be applicable to
inherited syndromes like FA, characterized by homology-directed DNA
repair (HDR) defects. Additionally, the existence of 16 different FA
genes, each of them with multiple mutations potentially accounting
for the disease, would imply the necessity of developing individualized
targeted gene therapy strategies in FA patients.
Results
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fibroblasts. This approach allowed us to develop a gene-editing plat-
form applicable to all FA subtypes and FA gene mutations based on
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over, gene-edited FA-A fibroblasts were reprogrammed to generate
disease-free iPSCs, which could be re-differentiated toward the hema-
topoietic lineage in a process that resulted in the generation of gene-
edited, disease-free, hematopoietic progenitor cells.
Impact
Our data showing that gene targeting is feasible in FA opens the
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tion of disease-free HSCs through the specific insertion of therapeutic
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additionally constitutes an implemented approach to overcome HSC
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